Transcriptional profiles and host-response biomarkers are used increasingly to investigate the severity, subtype and pathogenesis of disease. We now describe whole-blood mRNA signatures and concentrations of local and systemic immunological mediators in 131 adults hospitalized with influenza, from whom extensive clinical and investigational data were obtained by MOSAIC investigators. Signatures reflective of interferon-related antiviral pathways were common up to day 4 of symptoms in patients who did not require mechanical ventilator support; in those who needed mechanical ventilation, an inflammatory, activated-neutrophil and cell-stress or death (‘bacterial’) pattern was seen, even early in disease. Identifiable bacterial co-infection was not necessary for this ‘bacterial’ signature but was able to enhance its development while attenuating the early ‘viral’ signature. Our findings emphasize the importance of timing and severity in the interpretation of host responses to acute viral infection and identify specific patterns of immune-system activation that might enable the development of novel diagnostic and therapeutic tools for severe influenza.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Stöhr, K. Preventing and treating influenza. Br. Med. J. 326, 1223–1224 (2003).

  2. 2.

    Hayward, A. C. et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir. Med. 2, 445–454 (2014).

  3. 3.

    Dawood, F. S. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12, 687–695 (2012).

  4. 4.

    Bautista, E. et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362, 1708–1719 (2010).

  5. 5.

    Hui, D. S., Lee, N. & Chan, P. K. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 137, 916–925 (2010).

  6. 6.

    Peiris, J. S., Cheung, C. Y., Leung, C. Y. & Nicholls, J. M. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol. 30, 574–584 (2009).

  7. 7.

    Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16–32 (2012).

  8. 8.

    de Jong, M. D. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203–1207 (2006).

  9. 9.

    Ioannidis, I. et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J. Virol. 86, 5422–5436 (2012).

  10. 10.

    Ramilo, O. et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109, 2066–2077 (2007).

  11. 11.

    Zaas, A. K. et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6, 207–217 (2009).

  12. 12.

    Woods, C. W. et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One 8, e52198 (2013).

  13. 13.

    Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786–795 (2011).

  14. 14.

    Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195–204 (2014).

  15. 15.

    Obermoser, G. et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38, 831–844 (2013).

  16. 16.

    Blankley, S. et al. The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Phil. Trans. R. Soc. Lond. B 369, 20130427 (2014).

  17. 17.

    Pascual, V., Chaussabel, D. & Banchereau, J. A genomic approach to human autoimmune diseases. Annu. Rev. Immunol. 28, 535–571 (2010).

  18. 18.

    Everitt, A. R. et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519–523 (2012).

  19. 19.

    Ruggiero, T. et al. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. Influenza Other Respir. Viruses 7, 1416–1426 (2013).

  20. 20.

    Rykkvin, R., Kilander, A., Dudman, S.G. & Hungnes, O. Within-patient emergence of the influenza A(H1N1)pdm09 HA1 222G variant and clear association with severe disease, Norway. Euro Surveill. 18, 20369 (2013).

  21. 21.

    Herfst, S. et al. Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission. J. Virol. 84, 3752–3758 (2010).

  22. 22.

    Elderfield, R. A. et al. Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. J. Virol. 88, 13269–13283 (2014).

  23. 23.

    Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150–164 (2008).

  24. 24.

    Pankla, R. et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 10, R127 (2009).

  25. 25.

    Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P. & Lacroix, J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 39, 206–217 (2004).

  26. 26.

    Wu, M. H. et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir. Viruses 7, 349–355 (2013).

  27. 27.

    Falsey, A. R. et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J. Infect. Dis. 208, 432–441 (2013).

  28. 28.

    McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).

  29. 29.

    Marshall, J. C. Iatrogenesis, inflammation and organ injury: insights from a murine model. Crit. Care 10, 173 (2006).

  30. 30.

    Openshaw, P. J. & Chiu, C. Protective and dysregulated T cell immunity in RSVinfection. Curr. Opin. Virol. 3, 468–474 (2013).

  31. 31.

    Davidson, S., Crotta, S., McCabe, T. M. & Wack, A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 5, 3864 (2014).

  32. 32.

    Gregory, D. J. & Kobzik, L. Influenza lung injury: mechanisms and therapeutic opportunities. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1041–L1046 (2015).

  33. 33.

    Short, K. R., Kroeze, E. J. B. V., Fouchier, R. A. M. & Kuiken, T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect. Dis. 14, 57–69 (2014).

  34. 34.

    Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).

  35. 35.

    Biron, C. A. Interferons alpha and beta as immune regulators-a new look. Immunity 14, 661–664 (2001).

  36. 36.

    Narasaraju, T. et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol. 179, 199–210 (2011).

  37. 37.

    Lukens, M. V. et al. A systemic neutrophil response precedes robust CD8+ T-cell activation during natural respiratory syncytial virus infection in infants. J. Virol. 84, 2374–2383 (2010).

  38. 38.

    Tate, M. D., Brooks, A. G., Reading, P. C. & Mintern, J. D. Neutrophils sustain effective CD8+ T-cell responses in the respiratory tract following influenza infection. Immunol. Cell Biol. 90, 197–205 (2012).

  39. 39.

    Lim, K. et al. Neutrophil trails guide influenza-specific CD8+ T cells in the airways. Science 349, aaa4352 (2015).

  40. 40.

    Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014).

  41. 41.

    Carr, M. J. et al. Development of a real-time RT-PCR for the detection of swine-lineage influenza A (H1N1) virus infections. J. Clin. Virol. 45, 196–199 (2009).

  42. 42.

    Nguyen-Van-Tam, J. S. et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 65, 645–651 (2010).

  43. 43.

    Ashburner, M. et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).

Download references


MOSAIC Study was supported by a joint award from the Wellcome Trust and the Medical Research Council (090382/Z/09/Z). We gratefully acknowledge the support of the MOSAIC administrative team (M. Cross, L.-A. Cumming, M. Minns, T. Ford, B. Cerutti, D. Gardner and Z. Williams) and the generosity of our patients and their families, healthy volunteers, and staff at participating National Health Service (NHS) hospitals (Alder Hey Children's Hospital; Brighton & Sussex University Hospitals NHS Trust; Central Manchester University Hospitals NHS Foundation Trust; Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College Healthcare NHS Trust; Liverpool Women's NHS Foundation Trust; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Royal Brompton and Harefield NHS Foundation Trust; University Hospitals Coventry and Warwickshire NHS Trust). In particular, we thank K. Alshafi, S. Ashton, E. Bailey, A. Bermingham, M. Berry, C. Bloom, A. Booth, E. Brannigan, S. Bremang, J. Clark, M. Cross, L. A. Cumming, S. Dyas, J. England-Smith, J. Enstone, D. Ferreira, N. Goddard, A. Godlee, S. Gormley, M. Guiver, M. O. Hassan-Ibrahim, H. Hill, P. Holloway, K. Hoschler, G. Houghton, F. Hughes, R. R. Israel, A. Jepson, K. D. Jones, W. P. Kelleher, M. Kidd, K. Knox, A. Lackenby, G. Lloyd, H. Longworth, S. Mookerjee, S. Mt-Isa, D. Muir, A. Paras, V. Pascual, L. Rae, S. Rodenhurst, F. Rozakeas, E. Scott, E. Sergi, N. Shah, V. Sutton, J. Vernazza, A.W. Walker, C. Wenden, T. Wotherspoon, A. D. Wright and F. Wurie. We also thank E. Anguiano and members of the Genomic Core, BIIR, Dallas, for assistance with the microarray analysis; and M. Berry for guidance. We especially thank the MOSAIC Data Team (L. Drumright, L. Garcia-Alvarez, J. Lieber, S. Mookerjee and B. Pamba) for assistance in collating and validating clinical data; R. Smyth for careful review of the manuscript; and K. Strimmer for statistical advice in revisions of the manuscript. F. Rozakeas helped with recruiting samples from all the healthy control subjects at NIMR (Mill Hill). The MOSAIC consortium (ClinicalTrials.gov identifier NCT00965354) was supported by UK National Institute for Health Research (NIHR) Comprehensive Local Research Networks (CLRNs), the Biomedical Research Centre (NIHR Imperial BRC) and Unit (NIHR Liverpool BRU), the Health Protection Research Unit in Respiratory Infections in partnership with Public Health England (PHE) at Imperial College London (NIHR HPRU RI), the Health Protection Agency (latterly PHE) Microbiology Services, Colindale and the staff of the Roslin Institute, Edinburgh, Scotland. A.O.G. and C.G. were supported by the Medical Research Council, United Kingdom (U117565642), The Francis Crick Institute, London (AOG10126, which receives its core funding from Cancer Research UK (FC001126)), the UK Medical Research Council (FC001126), the Wellcome Trust (FC001126) and the UK Medical Research Council (MR/U117565642/1). S.B. was in part jointly funded by the UK Medical Research Council (MRC) as above and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (MR/J010723/1). C.B. was funded by an MRC CRTF. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, Public Health England or the Department of Health (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

MOSAIC investigators:

Maximillian S. Habibi, Sebastian L. Johnston, Trevor T. Hansel, Mike Levin, Ryan S. Thwaites, John O. Warner, William O. Cookson, Brian G. Gazzard, Alan Hay, John McCauley, Paul Aylin, Deborah Ashby, Wendy S. Barclay, R. A. Elderfield, Simon Nadel, Jethro A. Herberg, Lydia N. Drumright, Laura Garcia-Alvarez, Alison H. Holmes, Onn M. Kon, Stephen J. Aston, Stephen B. Gordon, Tracy Hussell, Catherine Thompson, Maria C. Zambon, Kenneth J. Baillie, David A. Hume, Peter Simmonds, Andrew Hayward, Rosalind L. Smyth, Paul S. McNamara, Malcolm G. Semple, Jonathan S. Nguyen-Van-Tam, Ling-Pei Ho, Andrew J. McMichael, Paul Kellam, Walt E Adamson, William F Carman and Mark J. Griffiths

Author information

Author notes

    • Jake Dunning

    Present address: National Infection Service, Public Health England, London, UK

  1. A list of MOSAIC members and affiliations appears at the end of the paper.


  1. Respiratory Infection Section, National Heart and Lung Institute, Imperial College London, London, UK

    • Jake Dunning
    • , Long T. Hoang
    • , Maximillian S. Habibi
    • , Sebastian L. Johnston
    • , Trevor T. Hansel
    • , Mike Levin
    • , Ryan S. Thwaites
    • , John O. Warner
    • , Onn M. Kon
    •  & Peter J. M. Openshaw
  2. Laboratory of Immunoregulation & Infection, The Francis Crick Institute, London, UK

    • Simon Blankley
    • , Christine M. Graham
    • , Chloe I. Bloom
    •  & Anne O’Garra
  3. Genomic Medicine, National Heart and Lung Institute, Imperial College London, London, UK

    • Mike Cox
    • , Philip L. James
    • , William O. Cookson
    •  & Miriam F. Moffatt
  4. Sidra Medical and Research Centre, Doha, Qatar

    • Damien Chaussabel
  5. The Jackson Laboratory for Genomic Medicine, Farmington, USA

    • Jacques Banchereau
  6. Surgery and Cancer, National Heart and Lung Institute, Imperial College London, London, UK

    • Stephen J. Brett
  7. Chelsea and Westminster NHS Foundation Trust, London, UK

    • Brian G. Gazzard
  8. Francis Crick Institute, World Influenza Centre, London, UK

    • Alan Hay
    •  & John McCauley
  9. School of Public Health, Imperial College London, London, UK

    • Paul Aylin
    •  & Deborah Ashby
  10. Department of Virology, Imperial College London, London, UK

    • Wendy S. Barclay
    •  & Ruth A. Elderfield
  11. Department of Paediatrics, Imperial College London, London, UK

    • Simon Nadel
    •  & Jethro A. Herberg
  12. Department of Respiratory Medicine, Imperial College Healthcare Trust, London, UK

    • Simon Nadel
    •  & Onn M. Kon
  13. Centre for Infection Prevention, Imperial College London, London, UK

    • Lydia N. Drumright
    • , Laura Garcia-Alvarez
    •  & Alison H. Holmes
  14. Respiratory Infection Group, Liverpool School of Tropical Medicine, Liverpool, UK

    • Stephen J. Aston
    •  & Stephen B. Gordon
  15. Manchester Collaborative Centre for Inflammation Research (MCCIR), Manchester, UK

    • Tracy Hussell
  16. Public Health England (formerly Health Protection Agency), London, UK

    • Catherine Thompson
    •  & Maria C. Zambon
  17. The Roslin Institute, University of Edinburgh, Edinburgh, UK

    • Kenneth J. Baillie
    • , David A. Hume
    •  & Peter Simmonds
  18. University College London, London, UK

    • Andrew Hayward
  19. UCL Institute of Child Health, London, UK

    • Rosalind L. Smyth
  20. University of Liverpool, Liverpool, UK

    • Paul S. McNamara
    •  & Malcolm G. Semple
  21. University of Nottingham, Nottingham, UK

    • Jonathan S. Nguyen-Van-Tam
  22. University of Oxford, Oxford, UK

    • Ling-Pei Ho
    •  & Andrew J. McMichael
  23. Wellcome Trust Sanger Institute, London, UK

    • Paul Kellam
  24. West of Scotland Specialist Virology Centre, Glasgow, UK

    • Walt E Adamson
    •  & William F Carman
  25. Royal Brompton and Harefield NHS Foundation Trust, London, UK

    • Mark J. Griffiths


  1. Search for Jake Dunning in:

  2. Search for Simon Blankley in:

  3. Search for Long T. Hoang in:

  4. Search for Mike Cox in:

  5. Search for Christine M. Graham in:

  6. Search for Philip L. James in:

  7. Search for Chloe I. Bloom in:

  8. Search for Damien Chaussabel in:

  9. Search for Jacques Banchereau in:

  10. Search for Stephen J. Brett in:

  11. Search for Miriam F. Moffatt in:

  12. Search for Anne O’Garra in:

  13. Search for Peter J. M. Openshaw in:


  1. MOSAIC Investigators


J.D., A.O.G. and P.J.M.O. conceived of and designed the study, with input from D.C. and J.B.; J.D., S.B., L.T.H. and C.I.B. analyzed the microarray data, with supervision by A.O.G. and P.J.M.O. and input from J.B. and D.C.; M.C., P.L.J. and M.F.M. performed and analyzed the microbiome experiments; C.M.G. performed the microarray experiments; J.D., S.J.B. and P.J.M.O. developed clinical protocols, recruited subjects and collated clinical data; and J.D., S.B., L.T.H., A.O.G. and P.J.M.O. wrote and revised the manuscript.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Anne O’Garra or Peter J. M. Openshaw.

Integrated supplementary information

  1. Supplementary Figure 1 Interferon signaling pathway.

    IPA canonical pathway for interferon signaling, identified as one of the top five canonical pathways for upregulated transcripts shown in Figure 1d (2010/11 cohort). Red shading represents up-regulated genes, blue represents down-regulated genes.

  2. Supplementary Figure 2 Validation of transcriptional signatures in an independent cohort.

    a) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 1255 transcript list (from Figure 1). (b) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 25 transcript list (from Figure 1). (c) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 231 transcript list of severity (from Figure 2, transcripts retained if >2FC between severity 3 and severity 1&2). GO Terms analysis of 3 major branches of the transcripts dendrogram was undertaken and listed next to the heat-map. (d) Using 51 and 112 transcripts lists (from Figure 3) ‘viral response’ and ‘bacterial response’ molecular scores were calculated and plotted for each influenza patient (relative to healthy controls). Cases were coded according to severity of illness, indicated by the colour of the respective dots (severity 1, black; severity 2, blue; severity 3, red).

  3. Supplementary Figure 3 Change of ‘viral’ and ‘bacterial’ molecular scores over time and association with influenza viral load.

    (a) ‘Viral’ molecular scores plotted for 59 influenza patients (2010/11 cohort) who provided T1 and T2 samples, plotted against respective day of illness at time of sampling. (b) Change in ‘viral’ molecular score between first (T1) and precise second time point (48 hours after T1) in 41 patients with appropriate samples available (P= 0.0002, Mann-Whitney test, two-tailed). (c) ‘Bacterial’ molecular score plotted for 59 influenza patients who had both a T1 and a T2 sample, shown plotted against respective day of illness. (d) Change in ‘bacterial’ molecular score between T1 and precise T2 (48h post T1), in 41 patients with appropriate samples available (NS, Mann-Whitney test, two-tailed). (e) Influenza viral load estimation (pfu/ml) in nasopharyngeal samples obtained at T1 (n=42) and T2 (n=40). Bars show the median and interquartile range. Zero values were reassigned a value of 0.001 for display purposes. Mann Whitney test (two-tailed); ** P=0.0094. (f) Relationship between influenza viral load (pfu/ml) at T1 or T2 and the simultaneous ‘viral’ molecular score on whole blood (n=82).

  4. Supplementary Figure 4 Administration of antibiotics does not affect ‘bacterial’ or ‘viral’ molecular scores.

    (a) Influenza patients (2010/11 cohort) presenting within the first 14 days of illness grouped by administration of any antibiotic (n=35) or no administration of antibiotics (n=35) in the 24 hours prior to T1 sampling. There was no difference (NS, Mann-Whitney test, two tailed) in either bacterial or viral molecular scores between the two groups. Bars show the median and interquartile range. (b) Prescription of antibiotics after T1 did not significantly influence ‘bacterial’ molecular score (P=0.9616, Kruskal Wallis test). Fifty-nine influenza patients who had both T1 and T2 samples were grouped by those who did not receive antibiotics (n=7), those whose antibiotics were stopped at T1 (n=1), those who had antibiotics prescribed after T1 but before T2 (n=24), and those who were receiving antibiotics at both T1 and T2 (N=27). Bars show median with interquartile range. (c) Total 16S rRNA copies at T1 in throat swabs and NP aspirate in patients adjudicated to be with or without bacterial co-infection. Those with confirmed bacterial infections (Bac +) had greater levels of total 16S rRNA copies in NP aspirate than those deemed to be without co-infection (Bac -) (Mann- Whitney test, P = 0.036). Throat swab Bac -, n=44; throat swab bac +, n=53; NP aspirate Bac -, n=17; NP aspirate Bac +, n=41.

  5. Supplementary Figure 5 Correlation of serum cytokines and bacterial load in nasophaynx with ‘viral’ and ‘bacterial’ molecular distance to health.

    (a) Levels of IL-17 in the serum of healthy controls (HC, n=36) and influenza infected patients (severity 1-3; n=59, n=43, and n=31, respectively). (b) Concentration of IL-17 in broncoalveolar lavage (BAL) of HC (n=11) and from influenza patients’ BAL (n=8), NPA (n=8), nasadsoprtion fluid (SAM; n=8) and serum (n=8). (c) Correlation of levels of IL-17 in serum (n=165) with the bacterial MDTH (Spearman R =0.39, P<0.001). (d) Correlation of levels of TNF-α in serum (n=165) with bacterial MDTH (Spearman R = 0.4, P<0.01). (e) Total 16S rRNA gene copies in NP aspirate samples (n=58) are inversely correlated with the viral MDTH (Spearman R = -0.28, P value < 0.05). (f) Total 16S rRNA gene copies in NP aspirate samples (n=58) are positively correlated with the bacterial MDTH (Spearman R = 0.37, P value < 0.05).

Supplementary information

  1. Supplementary Figures and Tables

    Supplementary Figures 1-5; Supplementary Tables 1 and 2

  2. Reporting Summary

  3. Supplementary Dataset

    Excel spreadsheet providing clinical data corresponding to raw and normalized microarray data deposited in GEO, Data Accession Code GSE111368.

About this article

Publication history






Further reading